Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
| Study Number Sort descending | Lead Group | Study Title | CIRB | Study Status | |
|---|---|---|---|---|---|
| ADVL0524 | COG | Phase II Trial of Ixabepilone (BMS-247550); an Epothilone B Analog; in Children and Young Adults with Refractory Solid Tumors | Pediatric CIRB | Completed | |
| ADVL0525 | COG | A Phase II Study of Pemetrexed in Children with Recurrent Malignancies | Pediatric CIRB | Completed | |
| ADVL06B1 | COG | A Pharmacokinetic-Pharmacodynamic-Pharmacogenetic Study of Actinomycin-D and Vincristine in Children with Cancer: A Group-Wide Non-Therapeutic Study | Pediatric CIRB | Completed | |
| ADVL0821 | COG | A Phase II Study of IMC-A12 (Anti-IGF-I Receptor Monoclonal Antibody; IND# 100947; NSC# 742460) in Children with Relapsed/Refractory Solid Tumors: A COG Groupwide Phase II Study | Pediatric CIRB | Completed | |
| ADVL0921 | COG | A Phase II Study of MLN8237 (IND# 102984); a Selective Aurora A Kinase Inhibitor in Children with Recurrent/Refractory Solid Tumors and Leukemias | Pediatric CIRB | Completed | |
| ADVL1121 | COG | A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (IND# 69896) in Children and Young Adults with Relapsed/Refractory Rhabdomyosarcoma; Wilms Tumor; Hepatocellular Carcinoma; and Papillary Thyroid Carcinoma | Pediatric CIRB | Completed | |
| ADVL1221 | COG | A Phase II Study of Cixutumumab (IMC-A12; IND# 100947) in Combination with Temsirolimus (IND# 61010) in Pediatric Patients with Recurrent or Refractory Solid Tumors | Pediatric CIRB | Completed | |
| ADVL1314 | COG | A Phase 1 Study of Eribulin Mesylate (E7389; IND #116;292); A Novel Microtubule Targeting Chemotherapeutic Agent in Children with Refractory or Recurrent Solid Tumors (Excluding CNS); Including Lymphomas: A Participation Limited to the COG Phase 1 Consortium | Pediatric CIRB | Completed | |
| ADVL1315 | COG | A Phase 1 Study of the VEGF Receptor Tyrosine Kinase Inhibitor Axitinib (INLYTA; 123101) in Children with Recurrent or Refractory Solid Tumors | Pediatric CIRB | Completed | |
| ADVL1412 | COG | A Phase 1/2 Study of Nivolumab (IND# 124729) in Children; Adolescents; and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab | Pediatric CIRB | Completed |